Barely Significant
← all excerpts

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.

Front Pharmacol · 2022 · PMC9624173 · PMID 36330085

Europe PMCDOI
1
hedged sentence
0.1900
closest p · 3.8× alpha
0.1900
boldest claim

The sentences

showed a trendp = 0.19not close (p > 0.1)
On the other hand, although treatment with tocilizumab showed a trend of improvement in the 28-day mortality as compared to that with the SOC, the improvement was not statistically significant [RR, 0.87 (95% CI, 0.71–1.07), p = 0.19] ( Figure 2B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.